Benjamin Derman to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications Benjamin Derman has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
3.486
-
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.
Score: 0.445
-
Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887.
Score: 0.419
-
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
Score: 0.403
-
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
Score: 0.396
-
Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program. JCO Oncol Pract. 2021 03; 17(3):e445-e453.
Score: 0.390
-
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).
Score: 0.373
-
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach? Best Pract Res Clin Haematol. 2019 12; 32(4):101102.
Score: 0.368
-
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol. 2026 Apr; 13(4):e241-e253.
Score: 0.143
-
The role of maintenance therapy and its cessation in patients with multiple myeloma. Leuk Lymphoma. 2025 Dec; 66(13):2426-2436.
Score: 0.138
-
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802.
Score: 0.121
-
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
Score: 0.099
-
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020 06 23; 4(12):2810-2820.
Score: 0.097
-
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498.
Score: 0.093